Your browser doesn't support javascript.
The Two-Way Switch Role of ACE2 in the Treatment of Novel Coronavirus Pneumonia and Underlying Comorbidities.
Pang, Xiao Cong; Zhang, Han Xu; Zhang, Zhi; Rinkiko, Suguro; Cui, Yi Min; Zhu, Yi Zhun.
  • Pang XC; School of Pharmacy and State Key Laboratory for the Quality Research of Chinese Medicine, Macau University of Science and Technology, Macau 999078, China.
  • Zhang HX; Department of Pharmacy, Peking University First Hospital, Beijing 100034, China.
  • Zhang Z; Department of Pharmacy, Peking University First Hospital, Beijing 100034, China.
  • Rinkiko S; School of Pharmaceutical Sciences, Tsinghua University, Beijing 100084, China.
  • Cui YM; School of Pharmacy and State Key Laboratory for the Quality Research of Chinese Medicine, Macau University of Science and Technology, Macau 999078, China.
  • Zhu YZ; Department of Pharmacy, Peking University First Hospital, Beijing 100034, China.
Molecules ; 26(1)2020 Dec 31.
Article in English | MEDLINE | ID: covidwho-1006941
ABSTRACT
December 2019 saw the emergence of the coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), which has spread across the globe. The high infectivity and ongoing mortality of SARS-CoV-2 emphasize the demand of drug discovery. Angiotensin-converting enzyme II (ACE2) is the functional receptor for SARS-CoV-2 entry into host cells. ACE2 exists as a membrane-bound protein on major viral target pulmonary epithelial cells, and its peptidase domain (PD) interacts SARS-CoV-2 spike protein with higher affinity. Therefore, targeting ACE2 is an important pharmacological intervention for a SARS-CoV-2 infection. In this review, we described the two-way switch role of ACE2 in the treatment of novel coronavirus pneumonia and underlying comorbidities, and discussed the potential effect of the ACE inhibitor and angiotensin receptor blocker on a hypertension patient with the SARS-CoV-2 infection. In addition, we analyzed the S-protein-binding site on ACE2 and suggested that blocking hot spot-31 and hot spot-353 on ACE2 could be a therapeutic strategy for preventing the spread of SARS-CoV-2. Besides, the recombinant ACE2 protein could be another potential treatment option for SARS-CoV-2 induced acute severe lung failure. This review could provide beneficial information for the development of anti-SARS-CoV-2 agents via targeting ACE2 and the clinical usage of renin-angiotensin system (RAS) drugs for novel coronavirus pneumonia treatment.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Antiviral Agents / Pneumonia / Angiotensin-Converting Enzyme 2 / SARS-CoV-2 / COVID-19 Drug Treatment Type of study: Prognostic study Limits: Animals / Humans Language: English Journal subject: Biology Year: 2020 Document Type: Article Affiliation country: Molecules26010142

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Antiviral Agents / Pneumonia / Angiotensin-Converting Enzyme 2 / SARS-CoV-2 / COVID-19 Drug Treatment Type of study: Prognostic study Limits: Animals / Humans Language: English Journal subject: Biology Year: 2020 Document Type: Article Affiliation country: Molecules26010142